EU Member States have tools to reduce costs of bestseller biologicals but can they use them?

Author(s): Adjunct Professor Pekka Kurki, MD, PhD

Abstract: Major cost savings are achievable in pharmacotherapy in the European Union since biosimilars to most best-selling biological medicinal products have been licensed. Unfortunately, the window of opportunity may be missed since neither national pricing, reimbursement and procurement systems nor prescribers are well prepared for biosimilars’ entry to the market. Submitted: 9 March 2018; Revised: […]

Read more →